A Phase IV, Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) With Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalation in Patients With Bipolar Depression.

Trial Profile

A Phase IV, Multi-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group Study to Compare the Tolerability of Quetiapine Fumarate Immediate Release (Seroquel IR) With Quetiapine Fumarate Extended Release (Seroquel XR) During Initial Dose Escalation in Patients With Bipolar Depression.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 May 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 27 Aug 2009 Actual end date (1 Aug 2009) added as reported by ClinicalTrials.gov.
    • 27 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Aug 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top